Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bg Med AkademijafiledCriticalBg Med Akademija
Priority to BG9563291ApriorityCriticalpatent/BG51775A1/en
Publication of BG51775A1publicationCriticalpatent/BG51775A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
The method is applied in medicine. It attains constant plasmic levels, ensuring optimal efficiency at lower proportions, by evading the punction trauma and the risk of infections. The erythropoietin is injected daily intranasally in a proportion of 20 to 25 units per kg of body weight until anaemia adjustment. Then supporting treatment with 10 to 15 units per kilogram of body weight is carried out.
BG9563291A1991-12-161991-12-16METHOD FOR TREATING OF ANAEMIC SYNDROME WITH HUMAN RECOMBINANT ERYTHROPOIETIN (ß)
BG51775A1
(en)